These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34348970)

  • 1. Combined Neurofilament Light and Optical Coherence Tomography Better Predicts Multiple Sclerosis Disease Activity Than Either Measure Alone.
    Krämer J; Wiendl H; Meuth SG; Albrecht P
    Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34348970
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurofilament light chain as a marker for cortical atrophy in multiple sclerosis without radiological signs of disease activity.
    Ineichen BV; Moridi T; Ewing E; Ouellette R; Manouchehrinia A; Stawiarz L; Ferreira D; Muehlboeck SJ; Kuhle J; Westman E; Leppert D; Hillert J; Olsson T; Kockum I; Piehl F; Granberg T
    J Intern Med; 2021 Aug; 290(2):473-476. PubMed ID: 33871105
    [No Abstract]   [Full Text] [Related]  

  • 3. Challenges and Opportunities for the Promising Biomarker Blood Neurofilament Light Chain.
    Abdelhak A; Kuhle J; Green AJ
    JAMA Neurol; 2023 Jun; 80(6):542-543. PubMed ID: 37010852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis.
    Berger T; Stüve O
    Neurology; 2019 Mar; 92(10):451-452. PubMed ID: 30737335
    [No Abstract]   [Full Text] [Related]  

  • 5. CSF neurofilament light: A universal risk biomarker in multiple sclerosis?
    Khalil M; Salzer J
    Neurology; 2016 Sep; 87(11):1068-9. PubMed ID: 27521432
    [No Abstract]   [Full Text] [Related]  

  • 6. Neurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosis.
    Soelberg Sorensen P; Sellebjerg F
    Mult Scler; 2016 Aug; 22(9):1112-3. PubMed ID: 27364323
    [No Abstract]   [Full Text] [Related]  

  • 7. Ongoing Axonal Injury in Chronic Active Lesions in Multiple Sclerosis: In Vivo Quantification Using Serum Neurofilament.
    Preziosa P; Schoonheim MM
    Neurology; 2021 Aug; 97(6):257-258. PubMed ID: 34088879
    [No Abstract]   [Full Text] [Related]  

  • 8. Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression: Clear as Mud.
    Goldschmidt C; Fox RJ
    Neurology; 2021 Nov; 97(19):887-888. PubMed ID: 34504029
    [No Abstract]   [Full Text] [Related]  

  • 9. A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
    Tavazzi E; Bergsland N; Kuhle J; Jakimovski D; Ramanathan M; Maceski AM; Tomic D; Hagemeier J; Kropshofer H; Leppert D; Dwyer MG; Weinstock-Guttman B; Benedict RHB; Zivadinov R
    J Neurol; 2020 Mar; 267(3):802-811. PubMed ID: 31768628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to Hyun J.W. et al. "Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis".
    Akgün K; Ziemssen T
    Mult Scler; 2020 May; 26(6):742-743. PubMed ID: 31144585
    [No Abstract]   [Full Text] [Related]  

  • 11. Neurofilament in clinical practice: Is the multiple sclerosis community ready?
    Moccia M; Terracciano D; Brescia Morra V; Castaldo G
    Mult Scler; 2024 May; 30(6):643-645. PubMed ID: 38605490
    [No Abstract]   [Full Text] [Related]  

  • 12. Reader Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Barro C
    Neurology; 2022 Oct; 99(14):630-631. PubMed ID: 36192183
    [No Abstract]   [Full Text] [Related]  

  • 13. Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Leppert D; Kropshofer H; Häring D; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J
    Neurology; 2022 Oct; 99(14):631. PubMed ID: 36192181
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum neurofilament light chain predicts cognitive worsening in secondary progressive multiple sclerosis better than brain MRI measures.
    Gaetani L; Schoonheim MM
    Mult Scler; 2022 Oct; 28(12):1831-1833. PubMed ID: 36124836
    [No Abstract]   [Full Text] [Related]  

  • 15. Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers.
    Novakova L; Axelsson M; Malmeström C; Imberg H; Elias O; Zetterberg H; Nerman O; Lycke J
    PLoS One; 2018; 13(4):e0194828. PubMed ID: 29614113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level-NO.
    Arrambide G; Espejo C; Tintore M
    Mult Scler; 2015 Sep; 21(10):1240-2. PubMed ID: 26242692
    [No Abstract]   [Full Text] [Related]  

  • 17. The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level - YES.
    Salzer J
    Mult Scler; 2015 Sep; 21(10):1239-40. PubMed ID: 25828757
    [No Abstract]   [Full Text] [Related]  

  • 18. Neurofilament light in blood - What more is needed for clinical implementation in multiple sclerosis?
    Zetterberg H
    EBioMedicine; 2020 Jul; 57():102826. PubMed ID: 32574951
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma neurofilament light in progressive multiple sclerosis.
    Zetterberg H
    Acta Neurol Scand; 2020 Jan; 141(1):14-15. PubMed ID: 31618445
    [No Abstract]   [Full Text] [Related]  

  • 20. The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary.
    Hutchinson M
    Mult Scler; 2015 Sep; 21(10):1242-3. PubMed ID: 26242693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.